NGEN

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts. VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGe

Leerink Partners initiated coverage of Nervgen Pharma with a rating of Outperform and set a new price target of $10.00

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

TD Cowen initiated coverage of Nervgen Pharma with a rating of Buy

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

EFFECT - NERVGEN PHARMA CORP. (0001751912) (Filer)

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

F-X - NERVGEN PHARMA CORP. (0001751912) (Subject)

F-10 - NERVGEN PHARMA CORP. (0001751912) (Filer)

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit. Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study. VA

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the d

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase co

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with results anticipated in 2Q 2026.Successfully listed on Nasdaq under the symbol 'NGEN' on January 8, 2026, and voluntarily delisted from the TSX Venture Exchange.Strengthened leadership team with three senior appointments to support late-stage clinical development and Nasdaq listing. VANCOUV

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

S-8 - NERVGEN PHARMA CORP. (0001751912) (Filer)

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

H.C. Wainwright initiated coverage of Nervgen Pharma with a rating of Buy and set a new price target of $18.00

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company's financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives. "We are thrilled to welcome Keith, an accomplished leader with deep operational and f